Better A1C, weight seen with canagliflozin treatment

04/15/2013 | MedWire News (U.K.)

Type 2 diabetes patients who used canagliflozin as an add-on to metformin/sulfonylurea treatment showed better A1C levels and body weight at 52 weeks than those who took sitagliptin, according to a study in Diabetes Care. Researchers also found 47.6% of canagliflozin-treated patients attained an A1C of less than 7%, compared with 35.3% in the sitagliptin group.

View Full Article in:

MedWire News (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT